Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression ☆ ☆This study was supported by the National Natural Science Foundation of China (No. 39870753) and Changhai Hospital ‘123’ Project.-Reference-Cited by-同舟云学术

Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression ☆ ☆This study was supported by the National Natural Science Foundation of China (No. 39870753) and Changhai Hospital ‘123’ Project.

Published:2001-12 Issue:12 Volume:66 Page:905-910
ISSN:0039-128X
Container-title:Steroids
language:en
Short-container-title:Steroids

Author:

Zheng Wei-qiang,Lu Jian,Zheng Jian-ming,Hu Feng-xian,Ni Chan-rong

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Pharmacology,Endocrinology,Molecular Biology,Biochemistry

Reference24 articles.

1. Estrogen receptor in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA;Gotteland;Cancer,1994

2. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer;Rutqvist;J Clin Oncol,1989

3. Endocrine resistance in advanced breast cancer;Dowsett;Acta Oncol,1996

4. Role of estrogen receptor variants in the development of hormone resistance in breast cancer;Sluyser;Clin Biochem,1992

5. Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast;Hoehn;Ann Surg,1979

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy;Frontiers in Oncology;2022-06-30

2. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors;Breast Cancer Research;2019-12

3. In search of the altering salivary proteome in metastatic breast and ovarian cancers;FASEB BioAdvances;2019-01-30

4. Breast cancer biomarker (ER, PR, HER2) changes in the phenotype after neoadjuvant treatment;Medical Council;2018-07-19

5. Post-menopausal breast cancer: from estrogen to androgen receptor;Oncotarget;2017-10-27